



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/538,245	06/07/2005	David Feifel	00015-067US/SD2003-090-1	3580
26138 7590 05/27/2009 Joseph R. Baker, APC Gavrilovich, Dodd & Lindsey LLP 4660 La Jolla Village Drive, Suite 750 San Diego, CA 92122				
EXAMINER DUTT, ADITI				
ART UNIT		PAPER NUMBER		
1649				
MAIL DATE		DELIVERY MODE		
05/27/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Interview Summary

Application No.

10/538,245

Applicant(s)

FEIFEL, DAVID

Examiner

Aditi Dutt

Art Unit

1649

All participants (applicant, applicant's representative, PTO personnel):

(1) Aditi Dutt.(3) Dr. David Feifel.(2) Jeffrey Stucker.(4) Joseph R. Baker.

Date of Interview: 22 May 2009.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal (copy given to: 1) ☐ applicant 2) ☐ applicant's representative)

Exhibit shown or demonstration conducted: d) ☒ Yes e) ☐ No.

If Yes, brief description: Power point slides to discuss the state of the art, novelty of Applicant's invention showing NT agonists can block the disruption of PPI produced by serotonin-2A agonist and alpha1 agonist.

Claim(s) discussed: 15-18, 22 and 24-26.

Identification of prior art discussed: See Continuation Sheet.

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

/A. D./
Examiner, Art Unit 1649

/Jeffrey Stucker/
Supervisory Patent Examiner, Art Unit 1649

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record

A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.

All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:

- 1) A brief description of the nature of any exhibit shown or any demonstration conducted,
- 2) an identification of the claims discussed,
- 3) an identification of the specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner,
(The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

Continuation of Identification of prior art discussed: 103 rejections:- Claims 15-16,18, 22, 24, 26, over Hertel et al (Eur J Pharmacol 422: 77-81, 2001) in view of Feifel et al (Brain Res 760: 80-84, 1997); Claims 15-17 and 25 over Hertel et al and Feifel et al, in view of Costa et al (Eur J Pharm 428: 97-103,2001) .

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments:

Inventor Dr. Feifel presented a talk to explain the state of the science with respect to the invention, taking into consideration the pending obviousness type rejections. Applicant tried to overcome the art rejection by explaining the differences in the underlying mechanism of action of neurotensin (NT). Since the prior art in the obviousness rejection teaches the reversal of amphetamine induced hyperactivity by NT69L, Applicant argued that it was already known that NT69L and other NT agonists blocked the amphetamine induced effects by inhibiting dopamine D2 receptors. On the other hand, the novelty of the instant invention lied in the demonstration that NT agonists function via inhibition of serotonin 2A, a finding first demonstrated by Applicant. Applicant further stated that the hyperactivity seen in rodents in the art is not correlated to human disorders, e.g. in anxiety disorders. Applicant was, however, notified that the claims had the limitation "subject" that would encompass both humans and non-humans. Claim amendments were discussed to overcome the rejection and project the novel aspect of the invention.

Following changes with regards to claim language were discussed:

- 1) Disease or disorder (claims have both term separated by an alternative. Clarification was sought).
- 2) Change of the term "subject" to "human" may be considered (This was considered because the hyperactivity behaviour observed in the animals as taught in the Hertel reference e.g. is not correlative to humans. Applicant was, however, cautioned that if the invention is pertaining to working with an animal model for treating symptoms in humans, and if the symptoms are not correlated to humans, the invention may not be enabled).
- 3) Suggestion was also made to submit an affidavit with references evidencing that the hyperactivity seen in animals is not observed in humans.
- 4) Because the novelty lies in NT inhibiting serotonin-2A receptor, possibility of inserting the serotonin aspect in claim 15 was contemplated.

Based upon the above stated discussion, Applicants agreed to amend claims and submit a supplementary response along with relevant references in about 10 days.